Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 12/05/23 07:00:00 on US and Canada Markets.
Grants of a quarter-million dollars each will fund new research at the University of Texas Health Science Center at Houston, Yale University and two schools at the University of North Carolina at Chapel Hill The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for...
Pilot Travel Centers LLC, General Motors and EVgo Make Convenient, Accessible Charging a Reality with Opening of First Stations in Coast-to-Coast EV Charging Network PR Newswire At least 25 locations offering 100 fast charging stalls by end of year; approximately 200 locatio...
Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan PR Newswire WASHINGTON , Dec. 5, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) , a company that specializes in bet...
NEW HISTORICAL NOVEL SHARES INSPIRING STORY OF THE SYRACUSE UNIVERSITY STAR, CIVIL RIGHTS PIONEER, AND AMERICAN HERO THAT HISTORY FORGOT PR Newswire SYRACUSE, N.Y. , Dec. 5, 2023 /PRNewswire/ -- A riveting historical novel based on the real story of Wilmeth Sid...
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (“Science 37” or the “Company”), the clinical research industry-leading Metasite™ , announced today that it will effect a 1-for-20 reverse stock split (&...
$2.3 million grant expected to drive research to harness the host interferon response as a pathway to treating and preventing pandemic influenza Exscientia plc (Nasdaq: EXAI) announced today that the Company received a $2.3 million grant from Open Philanthropy, a philanthropic funder wi...
BOCA RATON, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointe...
BDC-1001 is a Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) in Phase 2 development for HER2-positive breast, colorectal, endometrial, and gastroesophageal cancers Poster detailing trial design and rationale to be presented at the 2023 San Antonio Breast Cancer Symposium on Wed...
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints Positive data update for full 140 patients in ...
However, high housing costs will remain a problem for young families, which will increase demand for large rentals and force President Biden to make affordability a cornerstone of his reelection bid (NASDAQ: RDFN) — Signs point to a shift toward a buyer’s market in 2024 as...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.06%Change Percent:
Biogen Inc. Company Name:
BIIB Stock Symbol:
NASDAQ Market:
biogen.com Website: